“Fat but fit” didn’t pan out in a large Spanish study showing higher cardiovascular risk with overweight or obesity regardless of physical activity levels. (European Journal of Preventive Cardiology)
The American College of Cardiology’s political action committee is largely pausing campaign contributions, in the wake of blowback for supporting some individuals now seen as promoting violence in the Capitol and seeking to overturn the presidential election.
JACC: Heart Failure titled an editorial on the STAND-UP AHF with a riff on Donald Trump’s support for the Proud Boys, garnering jeers on Twitter.
The World Health Organization updated its treatment guidance on COVID-19 with a conditional recommendation for prophylactic anticoagulation rather than intermediate or therapeutic dosing in patients hospitalized with COVID-19, just days after announcement from three large trials that full-dose prophylaxis improved outcomes in that setting.
More evidence emerged, though, from a large observational study suggesting no advantage to therapeutic anticoagulation prophylaxis in the ICU for COVID-19. (Annals of Internal Medicine)
Minimally-invasive aortic valve surgery appeared safer in the mid-term than catheter-based replacement in a meta-analysis. (Open Heart)
Half of low-risk severe aortic stenosis patients at a single center had clinical criteria not studied in the key trials that have compared surgical and transcatheter treatment. (Journal of American College of Cardiology)
Novel inclisiran got a B+ for LDL lowering if it costs $3,600-$6,000 per year, according to the Institute for Clinical and Economic Review. Bempedoic acid (Nexletol) got a C+ but would need a 36% to 60% discount to make it worthwhile.
FDA approval for inclisiran — stalled over manufacturing issues — is unlikely before the third quarter of 2021. (Reuters)
While the FDA approved vericiguat (Verquvo) for recently decompensated HFrEF last week, competition will be fierce. (Endpoints News)
A survey of British heart failure patients indicated they were more anxious about COVID-19 than about their chronic disease. (ESC Heart Failure)
FDA approved Boston Scientific’s Synergy Megatron drug-eluting stent system for large, proximal vessels.
Echo-based screening and antibiotic prophylaxis for latent rheumatic heart disease at schools in Nepal was effective in a randomized trial. (JAMA Cardiology)
The Society for Cardiovascular Angiography and Interventions is releasing expert consensus recommendations on competencies for endovascular specialists providing chronic limb ischemia care but first wants your feedback.
Source: MedicalNewsToday.com
